SUCRAID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SUCRAID (SUCRAID).
SUCRAID (sacrosidase) is a yeast-derived enzyme that hydrolyzes sucrose into glucose and fructose, facilitating absorption in patients with congenital sucrase-isomaltase deficiency.
| Metabolism | Metabolized in the gastrointestinal tract; not systemically absorbed. Degraded by proteolytic enzymes and gastric acid. |
| Excretion | Primarily renal (minimal, as the drug acts locally in the GI tract). Less than 2% of the absorbed dose is excreted unchanged in urine; the majority is metabolized locally and excreted in feces. |
| Half-life | Intravenous administration: terminal half-life approximately 2.6 hours. Clinical context: Sacrosidase acts locally in the small intestine; systemic absorption is minimal. The short half-life reflects rapid clearance from plasma but does not correlate with intraluminal activity. |
| Protein binding | Not extensively studied; due to minimal systemic absorption, protein binding is expected to be low and clinically irrelevant. Estimated < 10% bound to plasma proteins (albumin). |
| Volume of Distribution | Not well characterized due to low systemic absorption; estimated Vd around 0.1 L/kg, suggesting limited distribution primarily within the extracellular space. Clinical meaning: minimal tissue penetration. |
| Bioavailability | Oral: less than 1% systemic bioavailability due to extensive local metabolism and lack of absorption; virtually 100% of the drug remains in the GI tract lumen. |
| Onset of Action | Oral: clinical effect (reduction of sucrose-induced gastrointestinal symptoms) within 30 to 60 minutes after administration with a meal. |
| Duration of Action | Oral: approximately 4 to 6 hours, corresponding to gastric emptying and small intestinal transit time. Clinical note: The drug is taken with each sucrose-containing meal. |
Adults: 1 mL (5 mg/mL) as an oral drop taken with the first bite of each meal. Maximum 5 mL per meal.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Children 1-4 years: 0.3 mL (1.5 mg) per meal. Children 4-12 years: 0.5 mL (2.5 mg) per meal. Children over 12 years: same as adult dose. |
| Geriatric use | No specific geriatric dose adjustment; use adult dosing with caution due to potential age-related gastrointestinal changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SUCRAID (SUCRAID).
| Breastfeeding | It is not known whether sacrosidase is excreted in human milk. Because the drug is minimally absorbed systemically, excretion into breast milk is unlikely. M/P ratio is not applicable due to lack of systemic absorption. Caution is advised, but the risk to the nursing infant is considered low. |
| Teratogenic Risk | Sucraid (sacrosidase) is a high molecular weight enzyme that is not systemically absorbed following oral administration. Due to negligible systemic exposure, it is not expected to pose a teratogenic risk. No fetal risks have been identified in animal studies, and there are no adequate human studies in pregnant women. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to sacrosidase or any ingredient in the formulation.","Allergy to yeast (Saccharomyces cerevisiae)."]
| Precautions | ["Hypersensitivity reactions (rare) including urticaria, angioedema, or anaphylaxis.","Not for intravenous or systemic use; administer orally with food.","Use with caution in patients with known allergies to yeast or yeast-derived products."] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond routine prenatal care, as systemic absorption is negligible. Monitor for gastrointestinal adverse effects in the mother, but no enhanced fetal surveillance is indicated. |
| Fertility Effects | No effects on fertility have been reported in animal studies or human data. Systemic exposure is minimal, suggesting no impact on reproductive function. |